Compare Biogen Inc (BIIB) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Garmin Ltd. — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Garmin Ltd. trades at $308 (market cap $59.72B). The key difference: Garmin Ltd. is the larger of the two by market cap, and Garmin Ltd. pays a 1.36% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GRMN | |
|---|---|---|
Market Cap | $30.13B | $59.72B |
Sector | Health | Technology |
52-Week High | $216.63 | $313.16 |
52-Week Low | $128.93 | $187.10 |
Enterprise Value | $37.20B | $57.23B |
Dividend Yield | — | 1.36% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
